Adaptive Biotechnologies Corporation Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for ADPT, updated each market day.
ADPT AI Sentiment
AI sees no strong directional signal for Adaptive Biotechnologies Corporation Common Stock stock over the next 10 market days.
Prediction date: Sept. 17, 2026
Exact scores are in the SharePreds app
The precise prediction score for this stock, with buy and sell targets and a stop loss, updated every market day.
About Adaptive Biotechnologies Corporation Common Stock
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
Sector
Exchange
Market Cap
$4,556,461,289
Cap Tier
Employees
624
Headquarters
SEATTLE, WA
Listed Since
June 27, 2019
Website
ADPT Sentiment Trend: Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
ADPT Volatility
Adaptive Biotechnologies Corporation Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings: this can present both opportunity and risk for traders.
